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license (http://creativefluid enclosing cerebral blood vessels and are potential imaging markers of various underlying brain
pathologies. Despite a growing interest in the study of enlarged VRS, the heterogeneity in rating and
quantification methods combined with small sample sizes have so far hampered advancement in the
field.
Methods: The Uniform Neuro-Imaging of Virchow-Robin Spaces Enlargement (UNIVRSE) con-
sortium was established with primary aims to harmonize rating and analysis (www.uconsortium.
org). The UNIVRSE consortium brings together 13 (sub)cohorts from five countries, totaling
16,000 subjects and over 25,000 scans. Eight different magnetic resonance imaging protocols were
used in the consortium.
Results: VRS rating was harmonized using a validated protocol that was developed by the two
founding members, with high reliability independent of scanner type, rater experience, or concomi-
tant brain pathology. Initial analyses revealed risk factors for enlarged VRS including increased age,
sex, high blood pressure, brain infarcts, and white matter lesions, but this varied by brain region.
Discussion: Early collaborative efforts between cohort studies with respect to data harmonization
and joint analyses can advance the field of population (neuro)imaging. The UNIVRSE consortium
will focus efforts on other potential correlates of enlarged VRS, including genetics, cognition, stroke,
and dementia.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).s article have nothing to declare.
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Neuroimaging allows for the in vivo assessment of brain
structure and function, thereby facilitating research on
neurodegenerative, psychiatric, and cerebrovascular dis-
eases. In the past decades, magnetic resonance imaging
(MRI) has identified both early and late markers of brain pa-
thology that have greatly contributed to our understanding of
the pathophysiology of neurologic diseases. White matter le-
sions, for example, are now a well-established marker of ce-
rebral small vessel disease, and hippocampal atrophy has
even been translated into a diagnostic marker of Alzheimer’s
disease. For several neuroimaging markers, standardized
definitions were recently proposed, but this was already after
decades of research using considerably heterogeneous
criteria [1]. Research on emerging neuroimaging markers
would benefit from harmonization early on. This article fo-
cuses on enlarged Virchow-Robin spaces (VRS), which
hold great potential as an MRI marker for various pathol-
ogies in the brain but remain poorly studied. VRS are
fluid-filled spaces enveloping the brain vasculature only to
become visible on MRI after a substantial increase in vol-
ume. Enlargement of these VRS was traditionally thought
to be an inconsequential finding on MRI, but this view has
repeatedly been questioned in recent years through estab-
lished links with cerebral small vessel disease, Alzheimer’s
disease, and multiple sclerosis, among others. Several the-
ories have been proposed for this enlargement, including
brain atrophy, inflammation, hypertension, and microvas-
cular obstruction (Fig. 1) [2–9]. Consequently, this
resulted in the study of enlarged VRS in relation to a
diverse range of diseases. However, the number of VRS
studies almost equals the number of methods used for their
assessment on MRI [2–4,10–13]. This has led to the
current inability to compare or pool results from different
studies, which are already limited in number and size.
Now, cohorts worldwide have joined efforts in trying to
harmonize VRS research early on, to overcome theseetiologies for enlargement of Virchow-Robin spaces.problems; an initiative which may be exemplary for future
population neuroimaging research.2. Methods
In 2010, the Rotterdam Scan Study (RSS) and Austrian
Stroke Prevention Study (ASPS), two large population-
based studies in aging populations, entered a collaboration
with the goal to develop a robust VRS rating method that
is reliable, incorporates relevant brain regions, and can be
easily applied by other researchers [14]. Briefly, enlarged
VRS are rated primarily on an axial T2-weighted sequence,
which shows VRS as hyperintensities, but this has now been
extended to allow T1-weighted images, where VRS are hy-
pointense, as the primary sequence. VRS are tubular struc-
tures that, depending on their orientation within the image,
can be linear, ovoid, or round in shape. VRS are considered
enlarged when their diameter is1 mm, to be able to distin-
guish “enlarged” VRS from “normal” VRS (Fig. 2). The
diameter is determined visually by the rater and not manu-
ally measured for every VRS because the latter would be
too time consuming. VRS are rated separately when these
are.3 mm because these large lesions potentially represent
different pathology. The shape of the lesion and its intensity
on the fluid-attenuated inversion recovery (FLAIR)
sequence are additionally used to differentiate between
enlarged VRS, lacunar infarcts, and white matter hyperin-
tensities.
During the development of our visual rating scale, we
focused on its reliability and ease of use. The number of
enlarged VRS is determined in four relevant brain regions:
the centrum semiovale, basal ganglia, hippocampus, and
mesencephalon. All unique enlarged VRS are counted in
the hippocampus and mesencephalon, whereas only a single,
predefined slice is used for the centrum semiovale and basal
ganglia, which are large brain regions for which counting on
all slices would be unfeasible. However, in a subset of 40
scans in which all VRS in the brain were counted, there
was a high correlation (0.79) between the number from
our single slice approach and the total number in that region,
indicating that the VRS burden for the larger regions
(centrum semiovale and basal ganglia) can be captured using
only a single slice. We rate the actual counts for each region
(either the whole region or a single slice), instead of catego-
rizing this into a severity score, so that this information is not
lost and can be analyzed continuously.
Furthermore, we are exploring the possibilities of an
automated segmentation method for detecting enlarged
VRS, similar to tools for white matter hyperintensities and
hippocampal size. This would allow for the investigation
of count and volume within the whole brain, as well as
Fig. 2. Virchow-Robin spaces in the centrum semiovale of various sizes. Panel A shows a person with faint (, 1 mm) Virchow-Robin spaces whereas panel B
shows a person with large ( . 1 mm) spaces.
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method and those of others have been shown to be reason-
ably reliable, we expect this objective, quantitative approach
to greatly reduce noise and increase analytical opportunities.
We believe automated detection will replace the visual rating
as the method of choice for determining enlarged VRS load
once this is ready to be applied within our consortium. A
recent study showed that high-resolution images obtained
from 7-T scanners are better suited for automated segmenta-
tion [15], although other efforts suggested that this might be
feasible with weaker field strengths [16].
Since the publication of this method, the founding mem-
bers have been joined by other cohorts that share an interest
in VRS research and acknowledge that questions regarding
their etiology and clinical relevance are best answered
through a combined effort. The Uniform Neuro-Imaging
of Virchow-Robin Spaces Enlargement (UNIVRSE) con-
sortium was formally established in 2013 and intends to
study enlarged VRS using a harmonized approach.
The UNIVRSE consortium currently consists of 13 (sub)
cohorts from five countries and encompasses .16,000 per-
sons with over 25,000 MRI scans (Table 1). It includes pro-
spective, population-based cohort and family studies from
various ethnicities and which have all previously been
described in detail. A brief overview is provided in the
following. Other cohorts that want to join the consortium
are referred to the consortium website (www.uconsortium.
org) for further details.2.1. Rotterdam Scan Study
The Rotterdam Study is a Dutch prospective, population-
based cohort study that aims to investigate causes and deter-
minants of diseases in the elderly [17]. A total of 14,926
subjects aged 45 years at baseline were recruited in three
subcohorts (1990, 2000, and 2006) and they are still being
followed up. MRI scanning is performed on all participantsfrom 2005 onward as part of the RSS and is repeated every
3–4 years [18].
2.2. Austrian Stroke Prevention Study
The ASPS is a prospective cohort study on the effects of
vascular risk factors on brain structure and function in cogni-
tively normal middle-aged and elderly inhabitants of Graz,
Austria [19]. In brief, 2007 subjects aged 50–75 years
without neuropsychiatric disease were randomly selected
from the official community register, of which a random sub-
set of 1076 participants underwent MRI in two panels
(1991–1994 and 1999–2003). Between 2006 and 2013, the
Austrian Stroke Prevention Family (ASPS-Fam) study was
recruited as an extension of ASPS using identical inclusion
criteria and diagnostic work-up with updatedMRI protocols;
ASPS-Fam included 381 members of the original ASPS
cohort and their relatives.
2.3. Study of Health in Pomerania
The Study of Health in Pomerania (SHIP) is a longitudi-
nal general population study from Greifswald, Germany that
enrolled 4308 middle-aged subjects in SHIP-0 (SHIP-0:
1997–2001; SHIP-1: 2003–2006; and SHIP-2: 2008–
2012). In addition to SHIP, a new cohort was started in
2008 (SHIP-Trend) with 4420 subjects [20]. In SHIP-2
and SHIP-Trend, whole body MRI scanning was performed
in 3317 subjects. The next follow-up starts in 2014/2015 and
includes a follow-up MRI scan.
2.4. Framingham Heart Study
The Framingham Heart Study (FHS) is a single-site, com-
munity-based, prospective cohort study initiated in 1948 to
investigate risk factors for cardiovascular disease and com-
prises three generations of participants. The original cohort
of the FHS, generation 1, consisted of 5209 participants
from Framingham MA who were enrolled into the study in
Table 1














rating sequence Voxel size (mm) Additional sequence(s)
ASPS
ASPS original Austria Population based 44–82 810 377 1.5 T2 weighted 0.9! 0.9! 5.5 T1 weighted, FLAIR
ASPS family Austria Population based 38–83 320 120 1.5 T2 weighted 0.8! 0.8! 3.0 T1 weighted, FLAIR
EPOZ Netherlands Population based 60–94 514 687 1.5 T2 weighted 1.0! 1.0! 1.25 T1 and proton density
weighted
ERF Netherlands Family study 55–75 129 — 1.5 T2 weighted 1.0! 1.0! 1.6 T1 weighted, FLAIR
FHS
Generation 1 USA Population based 79–103 353 224 1.5 T2 weighted 0.95! 0.95! 4.0 T1 weighted, FLAIR
Generation 2 USA Offspring 33–90 2749 2257 1.5 T2 weighted 0.95! 0.95! 4.0 T1 weighted, FLAIR
Generation 3 USA Offspring 19–63 2008 — 1.5 T2 weighted 0.95! 0.95! 4.0 T1 weighted, FLAIR
RS
RS-I Netherlands Population based 68–100 1236 198 1.5 T2 weighted 1.0! 1.0! 1.6 T1 weighted, FLAIR
RS-II Netherlands Population based 60–98 1493 1377 1.5 T2 weighted 1.0! 1.0! 1.6 T1 weighted, FLAIR
RS-III Netherlands Population based 46–94 3075 3714 1.5 T2 weighted 1.0! 1.0! 1.6 T1 weighted, FLAIR
SHIP
SHIP-2 Germany Population based 30–90 1163 Planned 1.5 T1 weighted 1.0! 1.0! 1.0 FLAIR
SHIP-Trend Germany Population based 21–82 2154 Planned 1.5 T1 weighted 1.0! 1.0! 1.0 FLAIR
EDIS Singapore Population based 60–85 865 — 3.0 T2 weighted 1.0! 1.0! 3.0 T1 weighted, FLAIR
Abbreviations: UNIVRSE, Uniform Neuro-Imaging of Virchow-Robin Spaces Enlargement; MRI, magnetic resonance imaging; VRS, Virchow-Robin
spaces; ASPS, Austrian Stroke Prevention Study; EPOZ, Epidemiological Prevention study Of Zoetermeer; ERF, Erasmus Rucphen Family; FHS, Framingham
Heart Study; RS, Rotterdam Study; SHIP, Study of Health in Pomerania; EDIS, Epidemiology of Dementia in Singapore.
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offspring of the original cohort and their spouses who were
enrolled into the study in 1971 (mean age, 36 years). Individ-
uals fromgenerations 1 and 2 received anMRI of the brain be-
tween 1999 and 2004 and again between 2005 and 2011
[21,22]. The generation 3 cohort was initiated in 2000, and
all subjectswere scanned between 2009andMarch, 2013 [23].2.5. Epidemiology of Dementia in Singapore study
The Epidemiology of Dementia in Singapore (EDIS)
study draws participants from the Singapore Epidemi-
ology of Eye Disease Study, which is a population-
based study among Chinese, Malays, and Indians [24].
EDIS aims to examine the prevalence of and investigate
risk factors for cognitive impairment and dementia in
these three major ethnicities of Singapore. A total of
865 subjects aged 60 years have been recruited between
2010 and 2013. Cranial MRI is performed in all the indi-
viduals.2.6. Erasmus Rucphen Family study
The Erasmus Rucphen Family (ERF) study is a family-
based cohort study in a genetically isolated population from
a community in the south-west of the Netherlands (Ruc-
phen municipality) including 3000 deeply phenotyped par-
ticipants. Participants with brain MRI scanning in ERF
aged 55–75 years and had hypertension to ensure a high
prevalence of pathology [25]. Persons with a history of
stroke or dementia or with MRI contraindications wereexcluded. Details about subject selection can be found else-
where [26,27].2.7. Epidemiological Prevention study Of Zoetermeer
The Epidemiological Prevention study Of Zoetermeer
(EPOZ) is a population-based follow-up study that was initi-
ated in 1975 [28]. It includes 10,361 subjects between 5 and
91 years old and originally focused on determinants of
various chronic diseases. Participants underwent baseline
MRI scanning in 1995–1996 and were rescanned in 1999–
2000 and 2008 [29,30].2.8. Statistical analyses
We will analyze enlarged VRS in a continuous manner
when studying their potential determinants by using nega-
tive binomial regression models that take into account the
continuous nature of our visual rating scale. Depending on
the specific research question, we will use the appropriate
statistical tools to analyze the data (e.g., Cox regression




Table 1 summarizes basic demographics and MRI proto-
cols for each study in the UNIVRSE consortium. The
consortium includes participants from a wide age range
(19–103 years), mainly sampled from a population-based
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of MRI scanning and most of the other cohorts are still
ongoing or reserve the possibility to perform an additional
round of follow-up. Furthermore, participants were often
part of other rounds of non-MRI data collection because
brain MRI was not always part of the core study protocol.
For most cohorts, a wide range of measurements are avail-
able, of which the most relevant are summarized in Table 2.
3.2. Primary outcomes
We previously developed a rating method that evaluates
four regions in the brain where enlarged VRS occur
frequently: the centrum semiovale, the basal ganglia, the
hippocampus, and the mesencephalon. The method was
rigorously tested by six raters ranging from medical students
to experienced specialists using MRI data from three
different scanners, and showed excellent reliability [14].
To promote the use of our VRS rating protocol, it has been
made freely accessible through our website (www.
uconsortium.org). Additionally, we have now extended the
rating protocol to MRI data from the SHIP study: enlarged
VRS were rated on the T1-weighted instead of the T2-
weighted sequence, which is the primary sequence for
VRS rating but was of too low resolution in SHIP for iden-
tifying VRS. To evaluate how this affects reliability, 25 scans
from the RS with both good quality T1- and T2-weighted se-Table 2
Nonexhaustive list of measurements available across the UNIVRSE consortium m
Phenotype ASPS ASPS family EDIS EPOZ
Demographics
Age U U U U
Gender U U U U
Education U U U U
Lifestyle factors
Smoking U U U U
Alcohol U U U U
Physical activity U U U U
Cognitive function U U U U
Blood chemistry
Cholesterol U U U U
Glucose U U U U
C-reactive protein U U U U
Cardiovascular
Blood pressure U U U U
Echocardiography ╳ ╳ ╳ U
Brain MRI markers
Intracranial volume U U U U
Tissue-specific volumes U U U U
Hippocampal volume U U U U
Infarcts U U U U
Microbleeds ╳ U U U
Genetics
Genome-wide SNP array U U U U
Exome chip ╳ U ╳ U
Abbreviations: UNIVRSE, Uniform Neuro-Imaging of Virchow-Robin Spaces E
of Dementia in Singapore; EPOZ, Epidemiological Prevention study Of Zoetermee
terdam Study; SHIP, Study of Health in Pomerania; MRI, magnetic resonance imquences were twice rated using each sequence separately,
with good reliability (mean intraclass correlation
coefficient 5 0.8).
The UNIVRSE consortium aims to elucidate the etiology
and clinical relevance of enlarged VRS. Therefore, it will
first investigate potential determinants of enlarged VRS,
including markers of cerebral small vessel disease, amyloid
pathology, and genetic factors. Results of a preliminary anal-
ysis from only the founding members showed region-
specific risk factors including sex, APOE genotype, blood
pressure, white matter hyperintensities, and lacunar infarcts
[31]. Additionally, the consortium is determining how pres-
ence of enlarged VRS affects cognition [3,32,33] and
whether it is a useful marker for predicting diseases such
as stroke [2,34,35] and Alzheimer’s disease [6].
4. Discussion
Here, we present our initial experiences with data
harmonization and joint analyses in a large consortium
of population neuroimaging studies. We used a robust vi-
sual rating method for measuring enlarged VRS, which
was rigorously tested in three studies before implementa-
tion in the consortium, to decrease heterogeneity and pro-
mote interstudy comparisons and collaboration.
Importantly, this collaboration was initiated already in a
relatively early phase of VRS research, with all theember cohorts
ERF FHS RS-I RS-II RS-III SHIP-2 SHIP-Trend
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U U U
U U U U U ╳ ╳
U U U U U U U
╳ U U ╳ ╳ U U
nlargement; ASPS, Austrian Stroke Prevention Study; EDIS, Epidemiology
r; ERF, Erasmus Rucphen Family; FHS, FraminghamHeart Study; RS, Rot-
aging; SNP, single nucleotide polymorphism.
Fig. 3. Comparison of statistical power between the UNIVRSE consortium
and the largest published study on Virchow-Robin spaces. Abbreviation:
UNIVRSE, Uniform Neuro-Imaging of Virchow-Robin Spaces Enlarge-
ment.
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ing their own methodology, but instead first harmonizing
ratings across sites and then jointly analyzing the data.
For other imaging markers of cerebrovascular disease,
such collaborative efforts typically follow decades of
research using heterogeneous methods [1]. Initial joint an-
alyses prove the value of this collaboration compared with
separate, underpowered efforts.
Although there is an abundance of VRS rating
methods, they are usually restricted to studies using
only a single MRI protocol and only rate the VRS in a
limited number of regions. Additionally, rating reliability
is not always reported and some methods require complex
transformations of images to perform the actual rating. A
crucial step in the development process was defining a
lower limit for the diameter of VRS to be considered
enlarged, which has not been done by any rating method
before. We operationalized enlargement as VRS
1 mm, while realizing this is an arbitrary threshold.
However, counting all enlarged VRS, regardless of size,
would mean that with increasing spatial resolution of
the used MRI scanner, persons would have more
“enlarged” VRS. Every study uses an implicit lower
bound because there is minimum size of enlarged VRS
that can be detected, which is inherent to the field strength
and protocol of the MRI scanner. Indeed, studies using a
3-T MRI have found a 100% prevalence of enlarged
VRS, in contrast with much lower prevalences on 1.5-T
images. Additionally, we found that using the T1-
weighted images for the primary rating gave comparable
results to T2-weighted images. This result further estab-
lishes our rating protocol as a method for reliably quanti-
fying VRS burden, regardless of the sequence used for
rating.
Furthermore, we focused on the ease of use and speed
of the method and rated VRS only a single slice for the
two larger regions (basal ganglia and centrum semiovale).
However, we have counted all VRS in the brain for 40
scans and compared this with the single slice that we
used in the rating. This showed a high correlation between
our single slice approach and the total number in that re-
gion. Although counting all VRS would be ideal, it is
extremely time consuming and given these results also
seems unnecessary to capture the VRS burden. Still, we
could have chosen the most severe slice instead of the pre-
defined slice that we use now. We made this decision
because of two reasons: (1) allowing the rater to choose
the “most severe” slice adds an additional layer of subjec-
tivity to the method and (2) it is currently unknown
whether the spatial distribution of VRS is differentially
related to pathology. If, for example, parietal VRS are
related to amyloid depositions, it would introduce bias
when only rating certain subjects with respect to that
part of the brain.
Main strengths of the UNIVRSE consortium are (1) the
increased statistical power to detect associations (Figure 3),achieved by combining data sets; (2) the harmonized
approach of enlarged VRS rating, which facilitates the collab-
oration and allows for better comparisons; and (3) the inclu-
sion of demographically diverse studies, with a broad range
of phenotypic information available.
Although our rating protocol has several advantages in
comparison with other scales, all methods still rely on the hu-
man assessment of VRS and are, therefore, subjective in na-
ture and labor intensive. However, we are concurrently
working on the development of an automated segmentation
method, which is particularly difficult for VRS. In addition,
the selection of the brain regions is basedmostly onprevalence
and current knowledge ofVRS; therefore, new research could,
for example, increase the interest in other regions and studying
different pathologymight also require changes in the protocol.
Our future research will include other determinants such
as markers of cerebral small vessel disease, amyloid pathol-
ogy, and genetic factors. In addition, we aim to determine
how presence of enlarged VRS affects cognition and
whether it is a useful marker for predicting diseases such
as Alzheimer’s disease and stroke.5. Conclusions
The UNIVRSE consortium is a global initiative that was
established in the young field of enlarged VRS research. It
aims to implement at an early stage the hard-learned lessons
on the value of data harmonization and joint analyses from
decades of population imaging.
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1. Systematic review: We searched for prospective,
population-based cohort and family studies from
various ethnicities. Particularly, we focused on
studies which have performed extensive data collec-
tion to enable us to gain more insight into risk factors
and consequences of enlarged Virchow-Robin
spaces.
2. Interpretation: The UNIVRSE consortium was initi-
ated to formally describe this collaboration between,
as of yet, 13 (sub) cohorts from five countries. The
consortium encompasses 16,000 research subjects
with over 25,000 MRI scans
3. Future directions: Early collaborative efforts be-
tween cohort studies with respect to data harmoniza-
tion and joint analyses can advance the field of
population (neuro) imaging. The UNIVRSE con-
sortium will focus efforts on other potential corre-
lates of enlarged VRS, including genetics,
cognition, stroke, and dementia.References
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